CTSO Stock — Cytosorbents Crp

Cytosorbents Crp (CTSO)

Updated October 16, 2026.

CTSO is a Stock. Total return is -94.6% over the past 20.2 years, 861.9 points behind SPY at 767.3%.

Cytosorbents Corporation develops and commercializes medical devices based on blood purification technology, with its flagship CytoSorb product designed to reduce harmful substances like cytokines and inflammatory mediators in critical illnesses, liver failure, and cardiac surgery applications, alongside investigational devices for bleeding reduction and organ preservation. The company does not currently distribute to shareholders. Cytosorbents operates as a medical device developer focused on healthcare applications rather than as an income-producing investment.

CTSO performance versus SPY

Price and return data through 2026-10-16.

Total return is -94.6% over the past 20.2 years, 861.9 points behind SPY at 767.3%. Over the past year its total return — price change plus distributions reinvested — is 353.9%. Its deepest 1-year drawdown was 61.3%.

CTSO key facts

Asset type

Stock

Asset class

Equity

Inception date

08/08/2006

Distribution frequency

None

Last close

$4.11 (as of 2026-10-16)

Market cap

$12,951,025

Average volume

678956.0

Beta

1.368

Payout ratio

0.0%

Forward P/E

7.1994

EPS

$-5.80

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CTSO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 61.3%.

Who may consider CTSO — and who may not

It is a weaker fit for investors who need monthly cash flow (CTSO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CTSO

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions